Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Janssen Biotech, Molecular Partners team up to develop DARPins for immunology indications; deal terminated

Executive Summary

Molecular Partners AG has agreed to use its technology to identify DARPins (Designed Ankyrin Repeat Proteins) for immunology disease targets of interest to Johnson & Johnson’s Janssen Biotech Inc. DARPins are like antibodies and have proven to have a higher efficacy to target tumors, inhibit viral and bacterial growth, and decrease inflammation.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies